IRIDEA develops small-molecule therapeutics targeting anti-angiogenic and anti-inflammatory pathways for chronic disorders. Their proprietary compounds are designed for cost-effective home administration, addressing unmet medical needs in diseases driven by dysregulated cell migration.
Funding
Funding not disclosed
Founders
Product
Problem
Many disorders are characterized by chronic inflammation or aberrant angiogenesis, often stemming from dysregulated cell migration. Current therapeutic strategies for these conditions are frequently inadequate, expensive, invasive, or require prolonged hospitalization.
Solution
IRIDEA is a drug discovery and development company focused on identifying small-molecule therapeutics with anti-angiogenic and anti-inflammatory properties. The company leverages a rational design process and standard organic chemistry methodologies to synthesize proprietary molecules. These compounds are designed to be cost-effective and facilitate home treatment, aiming to reduce the need for hospital admissions and intensive care. IRIDEA's approach prioritizes safety and aims to address unmet medical needs in a range of common and rare diseases.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and healthcare providers seeking novel therapeutic agents for inflammatory and angiogenesis-related disorders.
Features
- Development of small-molecule therapeutics targeting anti-angiogenic and anti-inflammatory pathways.
- Proprietary molecules selected through a rational design process.
- Synthesis of compounds utilizing standard organic chemistry methodologies.
- Focus on creating cost-effective drug substances.
- Design of molecules intended for convenient home administration.
- Research into the uPA/uPAR system's role in various pathologies.
- Development of biomimetic compounds that enhance natural biomolecular recognition.